Living Live: The Innovations Driving Remote Production Forward

 

On this episode of Living Live with Ross Video, host Tyler Kern was joined by Ross Video President and Executive Producer, Ross Mobile Productions Mitch Rubenstein and Stephen Repass, General Manager, Ross Mobile Productions.

The trio dove into the explosion of remote production, examining the journey of the industry to its current height and providing insights about where it might be headed.

“Over the course of the last several years, anyone who follows the industry and it a sports fan realizes that the advent of new networks has really increased the appetite that viewers have had for our type of product,” Rubenstein said. “Whether it’s an OTT platform, a new cable network, anything coming from a school-based production – you’re seeing more and more content on the air, which means more and more need for companies like ours.”

Specifically, Repass said, the boom in digital-only platforms has created a need for lean, efficient workflows and productions that can avoid spending resources in the way the traditional broadcast giants do.

“You can’t do a 53-foot truck and come in and spend $60,000-$70,000 on a show that’s going to air on a digital platform,” he said.

Even the mobile nature of the audience and a lack of traditional “time slots” plays a role, Rubenstein said – instead of producing content for a certain window, there are now unlimited possibilities for content to air and be seen.

To meet these needs, Ross Mobile Productions offers powerful, consistent and cost-effective solutions in the form of full-service production packages and rental services involving much smaller vehicles and operations.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More